2月4日,辉瑞公布了2024年业绩,第四季度营收177.63亿美元,同比增长21%,全年实现营收636.27亿美元,同比增长7%,若排除新冠口服药Paxlovid和新冠疫苗Comirnaty的影响,营收增长12%。《每日经济新闻》记者注意到,辉瑞此前收购的两家公司在2024年有不错的表现,合计贡献占公司7%的收入。其中,2023年收购的ADC(抗体偶联药物)公司Seagen,贡献了超34亿美元营收...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.